Abstract
OBJECTIVES This study aimed at estimating the real-life impact of vaccination on COVID-19 mortality, with adjustment for SARS-CoV-2 variants spread and other factors across Europe and Israel.
METHODS Time series analysis of daily number of COVID-19 deaths was performed using non-linear Poisson mixed regression models. Variants’ frequency, demographic, climate, health and mobility characteristics of thirty-two countries were considered as potentially relevant adjustment factors between January 2020 and April 2021.
RESULTS The analysis revealed that vaccination efficacy in terms of protection against deaths was equal to 72%, with a lower reduction of number of deaths for B.1.1.7 versus non-B.1.1.7 variants (70% and 78%, respectively). Other factors significantly related to mortality were arrivals at airports, mobility change from the pre-pandemic level and temperature.
CONCLUSIONS Our study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, although lower than expected from clinical trials. This suggests the absence of indirect protection for non-vaccinated individuals. Results also show that vaccination effectiveness against mortality associated with the B.1.1.7 variant is slightly lower compared with other variants. Lastly, this analysis confirms the role of mobility reduction, within and between countries, as an effective way to reduce COVID-19 mortality and suggests the possibility of seasonal variations in COVID-19 incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
katarzyna.jablonska{at}creativ-ceutical.com
samuel.aballea{at}creativ-ceutical.com
mondher.toumi{at}univ-amu.fr
Declaration of interests:
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Competing interests: None.
Ethical approval: Not required. This study does not require ethical approval as it was conducted on country-level data and involved information freely available in the public domain.
Contributors: MT conceptualized the study, KJ and SA validated the study concept, KJ and SA collected and analysed the data, KJ, SA and MT interpreted the results, KJ wrote the first draft of the manuscript, KJ, SA and MT revised the manuscript and approved the final version.
Data Availability
Authors confirm that the data used in this study are publicly available and all data sources were listed within the manuscript.
